The Role of Immunotherapy in Urologic Cancers

Review

. 2020 Mar-Apr;117(2):127-132.

The Role of Immunotherapy in Urologic Cancers

Allison May¹, Loren Roustio¹, Zachary A Hamilton¹

Affiliations

Affiliation

¹ Allison May, MD, Loren Roustio, BS, and Zachary A Hamilton, MD, are in the Division of Urology, Department of Surgery, Saint Louis University School of Medicine, St. Louis, Missouri.

PMID: 32308237
PMCID: PMC7144716

Review

The Role of Immunotherapy in Urologic Cancers

Allison May et al. Mo Med. 2020 Mar-Apr.

. 2020 Mar-Apr;117(2):127-132.

Authors

Allison May¹, Loren Roustio¹, Zachary A Hamilton¹

Affiliation

¹ Allison May, MD, Loren Roustio, BS, and Zachary A Hamilton, MD, are in the Division of Urology, Department of Surgery, Saint Louis University School of Medicine, St. Louis, Missouri.

PMID: 32308237
PMCID: PMC7144716

Abstract

In recent decades, there has been significant growth in the understanding of the immune system and its role in cancer. The recent introduction of checkpoint inhibitors has drastically changed the treatment landscape of cancer as a whole. In this review, we discuss the major clinical developments of immunotherapy in urologic specific cancers, as well as address future directions in this field.

PubMed Disclaimer

Figures

See this image and copyright information in PMC

Cited by

Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors.
Morgenstern-Kaplan D, Kareff SA, Trabolsi A, Rodriguez E, Krause H, Ribeiro JR, Tan H, Antonarakis ES, Lou E, Nagasaka M, Algaze S, Lenz HJ, Liu SV, Halmos B, Hoon DSB, Seeber A, Ma PC, El-Deiry WS, Vanderwalde AM, Lopes G. Morgenstern-Kaplan D, et al. Oncologist. 2024 Nov 4;29(11):e1480-e1491. doi: 10.1093/oncolo/oyae168. Oncologist. 2024. PMID: 38986529 Free PMC article.
Influence of Androgen Deprivation Therapy on the PD-L1 Expression and Immune Activity in Prostate Cancer Tissue.
Sommer U, Ebersbach C, Beier AK, Baretton GB, Thomas C, Borkowetz A, Erb HHH. Sommer U, et al. Front Mol Biosci. 2022 Jun 28;9:878353. doi: 10.3389/fmolb.2022.878353. eCollection 2022. Front Mol Biosci. 2022. PMID: 35836932 Free PMC article.
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.
Powles T, Chang YH, Yamamoto Y, Munoz J, Reyes-Cosmelli F, Peer A, Cohen G, Yu EY, Lorch A, Bavle A, Homet Moreno B, Markensohn J, Edmondson M, Chen C, Cristescu R, Peña C, Lunceford J, Gunduz S. Powles T, et al. Nat Med. 2024 Sep;30(9):2508-2516. doi: 10.1038/s41591-024-03091-7. Epub 2024 Jun 1. Nat Med. 2024. PMID: 38823511 Free PMC article. Clinical Trial.
Immunological Safety Evaluation of Exosomes Derived From Human Umbilical Cord Mesenchymal Stem Cells in Mice.
Wang C, Hu X, Liu Y, Xiao Y, Jiang P, Lin Y, Liu X, Zhang Z, Li LC, Qi Z. Wang C, et al. Stem Cells Int. 2025 Apr 26;2025:9986368. doi: 10.1155/sci/9986368. eCollection 2025. Stem Cells Int. 2025. PMID: 40321170 Free PMC article.

References

1. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–183. - PubMed
1. Gandhi N, Morales A, Lamm D. Bacillus Calmette-Guerin immunotherapy for genitourinary cancer. BJU Int. 2013;112(3):288–297. - PubMed
1. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–62. - PubMed
1. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920. - PMC - PubMed
1. Powles T, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748–757. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central

[1] Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–183. - PubMed

[2] Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–183. - PubMed

[3] Gandhi N, Morales A, Lamm D. Bacillus Calmette-Guerin immunotherapy for genitourinary cancer. BJU Int. 2013;112(3):288–297. - PubMed

[4] Gandhi N, Morales A, Lamm D. Bacillus Calmette-Guerin immunotherapy for genitourinary cancer. BJU Int. 2013;112(3):288–297. - PubMed

[5] Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–62. - PubMed

[6] Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–62. - PubMed

[7] Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920. - PMC - PubMed

[8] Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920. - PMC - PubMed

[9] Powles T, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748–757. - PubMed

[10] Powles T, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748–757. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The Role of Immunotherapy in Urologic Cancers

Affiliation

The Role of Immunotherapy in Urologic Cancers

Authors

Affiliation

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources